TMEM59L promotes neuroendocrine differentiation and enzalutamide resistance in prostate cancer by regulating MUC1/β‐catenin/MYC axis

Xiuchen Guo, Yifan Liu, Jiacheng Huang, Zhiwei Chen, Haihong Liao, Yulin Xu, Xingang Cui, Yongjiang Yu · 2026

Read TMEM59L promotes neuroendocrine differentiation and enzalutamide resistance in prostate cancer by regulating MUC1/β‐catenin/MYC axis by Xiuchen Guo, Yifan Liu, Jiacheng Huang, Zhiwei Chen, Haihong Liao, Yulin Xu, Xingang Cui, Yongjiang Yu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13579383.txt.

Description

Xiuchen Guo and co-authors present a study the catalog lists under 2026. Advanced prostate cancer often resists the hormone drug enzalutamide. Resistance can flip the tumor into a nerve-like, aggressive type. The drivers of that flip were unclear. The team studies a membrane protein called TMEM59L. Data join bulk, single-cell, and spatial gene maps to place the protein in tumors. Resistant cell lines and mouse grafts test its function.

The protein pushes the nerve-like shift and drug resistance. It acts through a chain that joins a surface protein, a signal carrier, and a growth gene. Blocking that chain is a candidate counter-move. Oncologists get a named driver for a feared transition. Treatment-induced type change is a growing problem as hormone drugs improve. A driver with a mapped chain offers drug designers a concrete target list.

Catalog record

CREATORXiuchen Guo, Yifan Liu, Jiacheng Huang, Zhiwei Chen, Haihong Liao, Yulin Xu, Xingang Cui, Yongjiang Yu
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE71 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13579383

Browse the full library · About the Tower of Babel